Before risankizumab's introduction, there were ten biologic therapies approved for psoriasis, with two more in development. Do we really need all of these expensive therapies for this disease? A close look at the data shows that we do not have any treatments that reliably achieve complete clearing as evidenced by psoriasis area and severity index (PASI) 100, and only the newest treatments achieve PASI 90 in high proportions of patients. Moreover, many treatments require frequent injections or are less effective in patients who have not had success with other therapies.